AU2013295035B2 - Glucagon analogues - Google Patents

Glucagon analogues Download PDF

Info

Publication number
AU2013295035B2
AU2013295035B2 AU2013295035A AU2013295035A AU2013295035B2 AU 2013295035 B2 AU2013295035 B2 AU 2013295035B2 AU 2013295035 A AU2013295035 A AU 2013295035A AU 2013295035 A AU2013295035 A AU 2013295035A AU 2013295035 B2 AU2013295035 B2 AU 2013295035B2
Authority
AU
Australia
Prior art keywords
aib
hypoglycaemia
glu
seq
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013295035A
Other languages
English (en)
Other versions
AU2013295035A1 (en
Inventor
Lise GIEHM
Ditte Riber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zealand Pharma AS
Original Assignee
Zealand Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zealand Pharma AS filed Critical Zealand Pharma AS
Publication of AU2013295035A1 publication Critical patent/AU2013295035A1/en
Application granted granted Critical
Publication of AU2013295035B2 publication Critical patent/AU2013295035B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
AU2013295035A 2012-07-23 2013-07-23 Glucagon analogues Active AU2013295035B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261674706P 2012-07-23 2012-07-23
US61/674,706 2012-07-23
US201361785611P 2013-03-14 2013-03-14
US61/785,611 2013-03-14
DKPA201300360 2013-06-14
DKPA201300360 2013-06-14
PCT/EP2013/065519 WO2014016300A1 (en) 2012-07-23 2013-07-23 Glucagon analogues

Publications (2)

Publication Number Publication Date
AU2013295035A1 AU2013295035A1 (en) 2015-02-12
AU2013295035B2 true AU2013295035B2 (en) 2017-08-03

Family

ID=49996630

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013295035A Active AU2013295035B2 (en) 2012-07-23 2013-07-23 Glucagon analogues

Country Status (27)

Country Link
US (3) US10442847B2 (OSRAM)
EP (1) EP2875043B1 (OSRAM)
JP (3) JP6534927B2 (OSRAM)
KR (1) KR102129235B1 (OSRAM)
CN (2) CN104662038B (OSRAM)
AR (1) AR091866A1 (OSRAM)
AU (1) AU2013295035B2 (OSRAM)
BR (1) BR112015001451B1 (OSRAM)
CA (1) CA2878991C (OSRAM)
DK (1) DK2875043T3 (OSRAM)
EA (1) EA033399B1 (OSRAM)
ES (1) ES2620111T3 (OSRAM)
FI (1) FIC20240034I1 (OSRAM)
FR (1) FR24C1043I2 (OSRAM)
IL (1) IL236554B (OSRAM)
IN (1) IN2015DN00544A (OSRAM)
MX (1) MX356957B (OSRAM)
MY (1) MY170671A (OSRAM)
NL (1) NL301294I2 (OSRAM)
NZ (1) NZ704043A (OSRAM)
PH (1) PH12015500115B1 (OSRAM)
PL (1) PL2875043T3 (OSRAM)
SG (1) SG11201500375PA (OSRAM)
TW (1) TWI642682B (OSRAM)
UA (1) UA117103C2 (OSRAM)
WO (1) WO2014016300A1 (OSRAM)
ZA (1) ZA201702364B (OSRAM)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012000564A (es) 2009-07-13 2012-04-11 Zealand Pharma As Analogos de glucagon acilados.
MX356641B (es) 2012-05-03 2018-06-07 Zealand Pharma As Compuestos agonistas dobles de gip-glp-1 y procedimientos.
JP6534927B2 (ja) * 2012-07-23 2019-06-26 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
RU2652783C2 (ru) 2012-12-21 2018-05-03 Санофи Двойные агонисты glp1/gip или тройные агонисты glp1/gip/глюкагона
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
WO2015055801A1 (en) 2013-10-17 2015-04-23 Zealand Pharma A/S Acylated glucagon analogues
WO2015067715A2 (en) 2013-11-06 2015-05-14 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
TR201902516T4 (tr) 2013-11-06 2019-03-21 Zealand Pharma As Glukagon-glp-1-gıp üçlü agonist bileşikleri.
TW201609796A (zh) 2013-12-13 2016-03-16 賽諾菲公司 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
US10570184B2 (en) 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
US10253078B2 (en) 2014-10-29 2019-04-09 Zealand Pharma A/S GIP agonist compounds and methods
CN107636010B (zh) 2015-04-16 2021-10-01 西兰制药公司 酰化胰高血糖素类似物
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
TWI622596B (zh) * 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
EP3638291B1 (en) 2017-06-16 2021-08-18 Zealand Pharma A/S Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues
GB201710822D0 (en) * 2017-07-05 2017-08-16 Zealand Pharma As Methods and medical uses relating to the treatment of hypoglycaemia
CN110913888A (zh) 2017-07-14 2020-03-24 Xeris药物公司 治疗先天性高胰岛素血症的方法
WO2019147718A1 (en) * 2018-01-23 2019-08-01 Xeris Pharmaceuticals, Inc. Treatment of post-bariatric hypoglycemia using mini-dose stable glucagon
ES3041327T3 (en) * 2020-03-16 2025-11-11 Zealand Pharma As Liquid formulations of glucagon analogues
KR20230121824A (ko) * 2020-12-16 2023-08-21 질랜드 파마 에이/에스 Glp-1/glp-2 이중 효능제의 약학적 조성물
CA3221829A1 (en) * 2021-06-18 2022-12-22 Weibing LIU Glucagon analog and medical use thereof
CN113501871B (zh) * 2021-07-21 2022-10-28 汉肽生物医药集团有限公司 一种固液相结合制备达西高血糖素的方法
WO2025056677A1 (en) 2023-09-15 2025-03-20 Zealand Pharma A/S Dasiglucagon for use in the treatment of congenital hyperinsulinism
WO2025189109A1 (en) * 2024-03-08 2025-09-12 The Trustees Of Indiana University Glucagon analogues compatible with prandial insulin co-infusion

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011117417A1 (en) * 2010-03-26 2011-09-29 Novo Nordisk A/S Novel glucagon analogues

Family Cites Families (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4288627A (en) 1980-02-12 1981-09-08 Phillips Petroleum Company Oxidation of thiols employing cobalt molybdate/triethylamine catalyst
NZ202757A (en) 1981-12-23 1985-11-08 Novo Industri As Peptides and medicaments
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
EP0512042B1 (en) 1990-01-24 1998-04-08 BUCKLEY, Douglas I. Glp-1 analogs useful for diabetes treatment
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
DE69107455T3 (de) 1990-05-09 2004-09-23 Novozymes A/S Eine ein endoglucanase enzym enthaltende zellulasezubereitung.
DK36392D0 (da) 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
US5846747A (en) 1992-03-25 1998-12-08 Novo Nordisk A/S Method for detecting glucagon-like peptide-1 antagonists and agonists
DK39892D0 (da) 1992-03-25 1992-03-25 Bernard Thorens Peptid
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
AU7531094A (en) 1993-08-24 1995-03-21 Novo Nordisk A/S Protracted glp-1
ZA946881B (en) 1993-09-07 1995-10-30 Amylin Pharmaceuticals Inc Methods for treating gastrointestinal motility
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5523449A (en) 1995-05-17 1996-06-04 Bayer Corporation Process for preparing phosphorodichlorido-dithioates by reacting alkylmercaptans with phosphorus trichloride in the presence of sulfur
CA2257119A1 (en) 1996-06-05 1997-12-11 Boehringer Mannheim Gmbh Exendin analogues, processes for their production and pharmaceutical preparations containing them
US6110703A (en) 1996-07-05 2000-08-29 Novo Nordisk A/S Method for the production of polypeptides
CA2262647C (en) 1996-08-08 2007-12-04 Amylin Pharmaceuticals, Inc. Methods for regulating gastrointestinal motility
US6277819B1 (en) 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6384016B1 (en) 1998-03-13 2002-05-07 Novo Nordisk A/S Stabilized aqueous peptide solutions
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
DE69737479T4 (de) 1996-08-30 2010-05-06 Novo Nordisk A/S Glp-1 derivate
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6006753A (en) 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
JP2001505872A (ja) 1996-09-09 2001-05-08 ジーランド ファーマシューティカルズ アクティーゼルスカブ α―ヒドロキシ酸リンカーを含むペプチドプロドラッグ
JP4405594B2 (ja) 1996-09-09 2010-01-27 ジーランド ファーマ アクティーゼルスカブ 改良型固相ペプチド合成及びかかる合成において利用するための試薬
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
AU5065198A (en) 1996-11-15 1998-06-10 Maria Grazia Masucci Fusion proteins having increased half-lives
PT1629849E (pt) 1997-01-07 2013-07-09 Amylin Pharmaceuticals Llc Composições farmacêuticas que compreendem exendinas e seus agonistas
US6136784A (en) 1997-01-08 2000-10-24 Amylin Pharmaceuticals, Inc. Amylin agonist pharmaceutical compositions containing insulin
US6410511B2 (en) 1997-01-08 2002-06-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
CA2279836A1 (en) 1997-02-05 1998-08-13 1149336 Ontario Inc. Polynucleotides encoding proexendin, and methods and uses thereof
US5846937A (en) 1997-03-03 1998-12-08 1149336 Ontario Inc. Method of using exendin and GLP-1 to affect the central nervous system
WO1998050351A1 (en) 1997-05-07 1998-11-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., Berlin New cysteine derivatives, processes for their production, and pharmaceuticals containing them
US7157555B1 (en) 1997-08-08 2007-01-02 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
JP2001513512A (ja) 1997-08-08 2001-09-04 アミリン・ファーマシューティカルズ，インコーポレイテッド 新規なエキセンディン作動剤化合物
ES2294822T3 (es) 1997-11-14 2008-04-01 Amylin Pharmaceuticals, Inc. Compuestos novedosos de agonistas de exendina.
US7223725B1 (en) 1997-11-14 2007-05-29 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
BR9814189A (pt) 1997-11-14 2000-10-03 Amylin Pharmaceuticals Inc "compostos agonistas da exendina"
US7220721B1 (en) 1997-11-14 2007-05-22 Amylin Pharmaceuticals, Inc. Exendin agonist peptides
CA2312190A1 (en) 1997-12-05 1999-06-17 Eli Lilly And Company Glp-1 formulations
CA2320371C (en) 1998-02-13 2012-01-17 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and glp-1
US6703359B1 (en) 1998-02-13 2004-03-09 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
AU2610899A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S N-terminally modified glp-1 derivatives
JP2003522099A (ja) 1998-02-27 2003-07-22 ノボ ノルディスク アクティーゼルスカブ 遅延作用プロファイルを有するｇｌｐ−１のｇｌｐ−１誘導体及びエキセンジン
JP4394279B2 (ja) 1998-03-09 2010-01-06 ジーランド ファーマ アクティーゼルスカブ 酵素加水分解に対する傾向が減少した薬理学的に活性なペプチド複合体
WO1999049788A1 (en) 1998-03-30 1999-10-07 Focus Surgery, Inc. Ablation system
SE9802080D0 (sv) 1998-06-11 1998-06-11 Hellstroem Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
ES2335066T3 (es) 1998-08-10 2010-03-18 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Diferenciacion de celulas no productoras de insulina en celulas productoras de insulina glp-1 o exendina-4 y utilizaciones de las mismas.
US6410508B1 (en) 1998-10-07 2002-06-25 Med College Georgia Res Inst Glucose-dependent insulinotropic peptide for use as an osteotropic hormone
US6284725B1 (en) 1998-10-08 2001-09-04 Bionebraska, Inc. Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
IL143346A0 (en) 1998-12-07 2002-04-21 Sod Conseils Rech Applic Analogues of glp-1
US7399489B2 (en) 1999-01-14 2008-07-15 Amylin Pharmaceuticals, Inc. Exendin analog formulations
CN101181236A (zh) 1999-01-14 2008-05-21 安米林药品公司 新型exendin激动剂制剂及其给药方法
CA2356331C (en) 1999-01-14 2009-10-13 Amylin Pharmaceuticals, Inc. Methods for glucagon suppression
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
EP1163211B1 (en) 1999-03-17 2008-09-24 Novo Nordisk A/S Method for acylating peptides and proteins
US6451974B1 (en) 1999-03-17 2002-09-17 Novo Nordisk A/S Method of acylating peptides and novel acylating agents
US6271241B1 (en) 1999-04-02 2001-08-07 Neurogen Corporation Cycloalkyl and aryl fused aminoalkyl-imidazole derivatives: modulators and GLP-1 receptors
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
CN1372570A (zh) 1999-04-30 2002-10-02 安米林药品公司 修饰的exendin和exendin激动剂
SI1180121T1 (en) 1999-05-17 2004-04-30 Conjuchem, Inc. Long lasting insulinotropic peptides
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
US6506724B1 (en) 1999-06-01 2003-01-14 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
US6344180B1 (en) 1999-06-15 2002-02-05 Bionebraska, Inc. GLP-1 as a diagnostic test to determine β-cell function and the presence of the condition of IGT and type II diabetes
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
ES2347137T3 (es) 2000-10-20 2010-10-26 Amylin Pharmaceuticals, Inc. Tratamiento de miocardio hibernante y cardiomiopatia diabetica con un peptido gpl-1.
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
AU2002346491A1 (en) 2001-12-19 2003-07-09 Eli Lilly And Company Crystalline compositions for controlling blood glucose
MXPA04006084A (es) 2001-12-20 2005-03-31 Lilly Co Eli Molecula de insulina que tiene una accion en el tiempo prolongada.
CA2490564A1 (en) 2002-07-04 2004-01-15 Zealand Pharma A/S Glp-1 and methods for treating diabetes
MXPA05003335A (es) 2002-10-02 2005-07-05 Zealand Pharma As Compuestos de exendina-4 estabilizados.
US7192922B2 (en) 2002-11-19 2007-03-20 Allegheny-Singer Research Institute Method of treating left ventricular dysfunction
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
EP1620465A2 (en) 2003-04-29 2006-02-01 Eli Lilly And Company Insulin analogs having protracted time action
AU2004243531B2 (en) * 2003-06-03 2009-11-05 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
US7623530B2 (en) 2003-11-20 2009-11-24 Nokia Corporation Indication of service flow termination by network control to policy decision function
WO2005072045A2 (en) 2004-01-30 2005-08-11 Waratah Pharmaceuticals, Inc. The combined use of glp-1 agonists and gastrin for regulating blood glucose levels
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
BRPI0517341A (pt) 2004-11-12 2008-10-07 Novo Nordisk As composição farmacêutica estável em prateleira, métodos para a preparação de uma composição farmacêutica, para o tratamento de hiperglicemia, para o tratamento de obesidade, deficiência de célula beta, igt ou dislipidemia, para a preparação de uma solução estável de um composto glp-1, para a preparação de um composto glp-1 estável e para a preparação de uma composição farmacêutica estável em prateleira de um composto glp-1, solução estável de um composto glp-1, e, uso de uma solução estável de um composto glp-1
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
JP2008539735A (ja) 2005-05-06 2008-11-20 バイエル・フアーマシユーチカルズ・コーポレーシヨン グルカゴン様ペプチド１（ｇｌｐ−１）受容体アンタゴニストおよびそれらの薬理学的使用方法
RU2485135C2 (ru) 2005-06-13 2013-06-20 Импиэриэл Инноувейшнс Лимитид Соединения оксинтомодулина (варианты), фармацевтическая композиция на их основе, способы лечения и профилактики ожирения и сопутствующих заболеваний (варианты) и лекарственное средство (варианты)
WO2007024899A2 (en) 2005-08-23 2007-03-01 The General Hospital Corporation Use of glp-1, glp-1 derivatives or glp-1 fragments for skin regeneration, stimulation of hair growth, or treatment of diabetes
EP2570133B1 (en) 2005-11-07 2016-03-23 Indiana University Research and Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
WO2007081824A2 (en) 2006-01-06 2007-07-19 Case Western Reserve University Fibrillation resistant proteins
WO2007095737A1 (en) 2006-02-21 2007-08-30 Waratah Pharmaceuticals Inc. Combination therapy for the treatment of diabetes comprising an exendin agonist and a gastrin compound
EP1991574B1 (en) 2006-02-22 2016-10-12 Merck Sharp & Dohme Corp. Oxyntomodulin derivatives
US8460667B2 (en) 2006-07-18 2013-06-11 Sanofi EPHA2 receptor antagonist antibodies
ITMI20061607A1 (it) 2006-08-09 2008-02-10 Maria Vincenza Carriero Peptidi con attivita farmacologica
ES2554773T3 (es) 2006-10-04 2015-12-23 Case Western Reserve University Insulina y análogos de la insulina resistentes a la fibrilación
UA102506C2 (ru) 2006-11-08 2013-07-25 Зиланд Фарма А/С Селективные аналоги глюкагоноподобного пептида-2 (glp-2)
WO2008071010A1 (en) 2006-12-12 2008-06-19 Waratah Pharmaceuticals Inc. Combination treatments with selected growth/hormone regulatory factors for diabetes and related diseases
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
CN101578102B (zh) * 2007-01-05 2013-07-17 印第安纳大学研究及科技有限公司 在生理性pH缓冲液中显示增强的溶解性的胰高血糖素类似物
US8454971B2 (en) 2007-02-15 2013-06-04 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
DK2158214T3 (da) 2007-06-15 2011-12-05 Zealand Pharma As Glukagonanaloger
EP2025684A1 (en) 2007-08-15 2009-02-18 Zealand Pharma A/S Glucagon analogues
FR2917552B1 (fr) 2007-06-15 2009-08-28 Sagem Defense Securite Procede de regulation de la gigue de transmission au sein d'un terminal de reception
EP2217265B1 (en) 2007-11-20 2017-05-10 Ambrx, Inc. Modified insulin polypeptides and their uses
GB2455553B (en) 2007-12-14 2012-10-24 Nuaire Ltd Motor mounting assembly for an axial fan
JP5695909B2 (ja) 2008-01-09 2015-04-08 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 極度に遅延した時間作用プロファイルを有する新規なインスリン誘導体
DE102008003566A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
DE102008003568A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
MY152979A (en) 2008-01-09 2014-12-15 Sanofi Aventis Deutschland Novel insulin derivatives having an extremely delayed time-action profile
US8993516B2 (en) 2008-04-14 2015-03-31 Case Western Reserve University Meal-time insulin analogues of enhanced stability
WO2009132129A2 (en) 2008-04-22 2009-10-29 Case Western Reserve University Isoform-specific insulin analogues
TWI451876B (zh) 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
EA019203B9 (ru) 2008-06-17 2014-03-31 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Коагонисты глюкагонового рецептора/glp-1-рецептора
AU2009260301B2 (en) 2008-06-17 2015-09-03 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers
CN104945500B (zh) 2008-06-17 2019-07-09 印第安纳大学研究及科技有限公司 基于gip的混合激动剂用于治疗代谢紊乱和肥胖症
PL219335B1 (pl) 2008-07-04 2015-04-30 Inst Biotechnologii I Antybiotyków Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, jej zastosowanie oraz zawierająca ją kompozycja farmaceutyczna
JP5780958B2 (ja) 2008-07-31 2015-09-16 ケイス、ウエスタン、リザーブ、ユニバーシティ ハロゲン安定化インスリン
CA2732949C (en) 2008-08-07 2016-12-20 Ipsen Pharma S.A.S. Analogues of glucose-dependent insulinotropic polypeptide
WO2010029159A1 (en) 2008-09-12 2010-03-18 Novo Nordisk A/S Method of acylating a peptide or protein
PL2370460T3 (pl) 2008-12-15 2014-09-30 Zealand Pharma As Analogi glukagonu
AU2008365555B2 (en) * 2008-12-15 2016-01-14 Zealand Pharma A/S Glucagon analogues
BRPI0823377A2 (pt) * 2008-12-15 2016-09-27 Zealand Pharma As análogos de glucagon
AU2008365557A1 (en) 2008-12-15 2011-07-21 Zealand Pharma A/S Glucagon analogues
CN102256992B (zh) 2008-12-19 2015-04-22 印第安纳大学研究及科技有限公司 胰岛素类似物
CN102245624B (zh) 2008-12-19 2016-08-10 印第安纳大学研究及科技有限公司 基于酰胺的胰岛素前药
WO2010096052A1 (en) 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Oxyntomodulin analogs
WO2010107487A2 (en) 2009-03-18 2010-09-23 Wu Nian Lipid-drug conjugates for drug delivery
CN101519446A (zh) 2009-03-31 2009-09-02 上海一就生物医药有限公司 一种重组人胰岛素及其类似物的制备方法
WO2010129904A1 (en) 2009-05-08 2010-11-11 Genentech, Inc. Humanized anti-egfl7 antibodies and methods using same
AU2010260058B2 (en) 2009-06-16 2015-09-24 Indiana University Research And Technology Corporation GIP receptor-active glucagon compounds
MX2012000564A (es) 2009-07-13 2012-04-11 Zealand Pharma As Analogos de glucagon acilados.
US8815802B2 (en) 2009-12-16 2014-08-26 Novo Nordisk A/S GLP-1 analogues and derivatives
US20110312881A1 (en) 2009-12-21 2011-12-22 Amunix, Inc. Bifunctional polypeptide compositions and methods for treatment of metabolic and cardiovascular diseases
CA2786934A1 (en) 2010-01-20 2011-07-28 Zealand Pharma A/S Treatment of cardiac conditions
IN2012DN06437A (OSRAM) 2010-01-27 2015-10-09 Univ Indiana Res & Tech Corp
EP2552950A1 (en) * 2010-03-26 2013-02-06 Novo Nordisk A/S Novel glucagon analogues
AR080592A1 (es) 2010-03-26 2012-04-18 Lilly Co Eli Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso
BR112012027545B1 (pt) 2010-04-27 2020-09-24 Betta Pharmaceuticals Co., Ltd. Composto, composição farmacêutica, uso da composição farmacêutica e uso de um composto
US9089538B2 (en) 2010-04-27 2015-07-28 Zealand Pharma A/S Peptide conjugates of GLP-1 receptor agonists and gastrin and their use
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
EA201291234A1 (ru) 2010-06-24 2013-07-30 Зилэнд Фарма А/С Аналоги глюкагона
WO2011163473A1 (en) * 2010-06-25 2011-12-29 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability in physiological ph buffers
WO2012062803A1 (en) 2010-11-09 2012-05-18 Novo Nordisk A/S Double-acylated glp-1 derivatives
AU2012208349A1 (en) 2011-01-20 2013-07-18 Zealand Pharma A/S Combination of acylated glucagon analogues with insulin analogues
BR112013024076A2 (pt) 2011-03-28 2016-12-06 Novo Nordisk As análogos de glucagon
CN106117344B (zh) 2011-04-12 2020-11-03 诺沃—诺迪斯克有限公司 双酰化glp-1衍生物
WO2012150503A2 (en) 2011-05-03 2012-11-08 Zealand Pharma A/S Glu-glp-1 dual agonist signaling-selective compounds
WO2012153196A2 (en) 2011-05-10 2012-11-15 Zealand Pharma A/S Glu-glp-1 dual agonist signaling-selective compounds
CN103764673A (zh) 2011-06-10 2014-04-30 北京韩美药品有限公司 葡萄糖依赖性促胰岛素多肽类似物、其药物组合物及应用
MX354705B (es) 2011-09-23 2018-03-16 Novo Nordisk As Analogos de glucagon novedosos.
US20130316941A1 (en) 2011-12-23 2013-11-28 Boehringer Ingelheim International Gmbh Glucagon analogues
WO2013098408A1 (en) * 2011-12-30 2013-07-04 Zealand Pharma A/S Glucagon and cck receptor agonist peptide conjugates
WO2013164484A1 (en) 2012-05-03 2013-11-07 Zealand Pharma A/S Glucagon-like-peptide-2 (glp-2) analogues
MX356641B (es) 2012-05-03 2018-06-07 Zealand Pharma As Compuestos agonistas dobles de gip-glp-1 y procedimientos.
JP6534927B2 (ja) 2012-07-23 2019-06-26 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
WO2015055801A1 (en) 2013-10-17 2015-04-23 Zealand Pharma A/S Acylated glucagon analogues
WO2015067715A2 (en) 2013-11-06 2015-05-14 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
BR112016016321A2 (pt) 2014-02-18 2017-10-03 Novo Nordisk As Derivados de análogos de glucagon estáveis, seus usos, e composição farmacêutica
CN107636010B (zh) 2015-04-16 2021-10-01 西兰制药公司 酰化胰高血糖素类似物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011117417A1 (en) * 2010-03-26 2011-09-29 Novo Nordisk A/S Novel glucagon analogues

Also Published As

Publication number Publication date
US10442847B2 (en) 2019-10-15
JP6534927B2 (ja) 2019-06-26
US11795204B2 (en) 2023-10-24
NL301294I2 (nl) 2024-11-18
EP2875043B1 (en) 2016-12-21
EP2875043A1 (en) 2015-05-27
TW201404785A (zh) 2014-02-01
MX356957B (es) 2018-06-20
BR112015001451B1 (pt) 2022-03-29
AR091866A1 (es) 2015-03-04
AU2013295035A1 (en) 2015-02-12
ZA201702364B (en) 2019-05-29
JP2022023029A (ja) 2022-02-07
FR24C1043I2 (fr) 2025-10-10
JP2015524419A (ja) 2015-08-24
EA201590058A1 (ru) 2015-09-30
HK1210787A1 (en) 2016-05-06
PH12015500115A1 (en) 2015-03-30
NZ704043A (en) 2017-07-28
TWI642682B (zh) 2018-12-01
DK2875043T3 (en) 2017-03-27
KR102129235B1 (ko) 2020-07-06
US20150210744A1 (en) 2015-07-30
FIC20240034I1 (fi) 2024-10-23
FR24C1043I1 (fr) 2024-12-06
CN104662038A (zh) 2015-05-27
CA2878991C (en) 2021-12-07
UA117103C2 (uk) 2018-06-25
SG11201500375PA (en) 2015-02-27
IN2015DN00544A (OSRAM) 2015-06-26
KR20150032912A (ko) 2015-03-30
CN109456400A (zh) 2019-03-12
IL236554B (en) 2020-04-30
US20200207825A1 (en) 2020-07-02
PH12015500115B1 (en) 2015-03-30
PL2875043T3 (pl) 2017-06-30
IL236554A0 (en) 2015-02-26
MY170671A (en) 2019-08-26
CN104662038B (zh) 2018-11-06
MX2015000990A (es) 2015-03-20
US20240067696A1 (en) 2024-02-29
JP2019187419A (ja) 2019-10-31
CA2878991A1 (en) 2014-01-30
BR112015001451A2 (pt) 2017-07-04
WO2014016300A1 (en) 2014-01-30
ES2620111T3 (es) 2017-06-27
EA033399B1 (ru) 2019-10-31

Similar Documents

Publication Publication Date Title
US20240067696A1 (en) Glucagon analogues
US8486890B2 (en) Amylin derivatives
AU2011206979B2 (en) Treatment of cardiac conditions
RU2559320C2 (ru) Новые аналоги глюкагона
AU2008365559B2 (en) Glucagon analogues
US20130053310A1 (en) Novel glucagon analogues
TW202118775A (zh) 升糖素及glp-1共激動劑化合物
AU2008365557A1 (en) Glucagon analogues
KR20060135661A (ko) 신규 ｇｌｐ-1 화합물
TW201733613A (zh) 用於治療肥胖之升糖素及glp-1共促效劑
TW201917134A (zh) 新穎的醯基化胰島素類似物及其用途
CN102076353A (zh) 胰岛淀粉样多肽和鲑鱼降钙素的衍生杂合肽
KR20200080331A (ko) 글루카곤 유사체
HK1210787B (en) Glucagon analogues
WO2024245233A1 (zh) 一种口服递送的多肽衍生物

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)